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Abstract To assess the effectiveness of a psychosocial
individual intervention to improve adherence to ART in a
Brazilian reference-center, consenting PLHIV with viral
load[50 copies/ml were selected. After 4 weeks of MEMS
cap use, participants were randomized into an intervention
group (IG) (n = 64) or control group (CG) (n = 57). CG
received usual care only. The IG participated in a human
rights-based intervention approach entailing four dialogical
meetings focused on medication intake scenes. Comparison
between IG and CG revealed no statistically significant
difference in adherence measured at weeks 8, 12, 16, 20
and 24. Viral load (VL) decreased in both groups
(p \ 0.0001) with no significant difference between study
groups. The lower number of eligible patients than
expected underpowered the study. Ongoing qualitative
analysis should provide deeper understanding of the trial
results. NIH Clinical Trials: NCTOO716040.
Resumen Personas viviendo con VIH con carga viral
[50 copias/ml fueron seleccionadas en un centro de ref-
erencia en Brasil para evaluar la efectividad de una inter-
vencio´n psicosocial individual para mejorar la adhesio´n a
la terapia antirretroviral. Los participantes firmaron el
documento de consentimiento informado. Tras 4 semanas
de uso de MEMS caps, los participantes fueron aleator-
izados en el grupo de intervencio´n (GI) (n = 64) o el grupo
control (GC) (n = 57). El CG recibio´ solamente los cui-
dados habituales. El GI participo´ de una intervencio´n
basada en los derechos humanos, con cuatro reuniones
dialo´gicas centradas en escenas de toma de medicamentos.
La comparacio´n entre GI y CG no revelo´ ninguna difer-
encia estadı´sticamente significativa en la adhesio´n medida
en las semanas 8, 12, 16, 20 y 24. La carga viral (CV)
disminuyo´ en ambos grupos del estudio (p \ 0.0001),
aunque sin significado estadı´stico. El nu´mero de pacientes
elegibles, ma´s pequen˜o del que el esperado, disminuyo´ el
poder del estudio. El ana´lisis cualitativo actual debe pro-
porcionar una comprensio´n ma´s profunda de los resultados
del estudio. Registro del Ensayo Clı´nico: NCT00716040.
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Introduction
Successful antiretroviral therapy outcomes depend on high
patient adherence to the treatment [1, 2], although recent
reports have demonstrated that moderate levels of adher-
ence can also promote viral suppression [3]. Low levels of
adherence have been shown to increase risk of disease
progression burden on services and treatment cost [4–8].
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Non-adherence facilitates the emergence of resistant strains
of the virus (limiting future treatment options) and pro-
vokes spread of the disease among the community [9].
Adherence has become crucial to AIDS programs world-
wide [10–12] and has led to the implementation of inter-
ventions aimed at enhancing adherence [13].
In Brazil, besides universal and free access to health
care and antiretroviral therapy, all PLHIV are also entitled
to free access to CD4, Viral Load and Genotyping exams.
The National AIDS Program has provided general guid-
ance to the health system regarding adherence [14].
As analyzed by Caraciolo [15], most AIDS care services
report that adherence is assessed and encouraged, mainly
during clinical consultations with physicians and nurses.
Additionally, services carry out different initiatives to
enhance adherence, such as group sessions or conversa-
tions and talks in the waiting room. Adherence promotion
activities however, differ greatly across local health ser-
vices, and are rarely evaluated. Moreover, most these
activities are aimed at all patients and there are no reports
of interventions aimed specifically at non-adherent
patients. Few studies have been performed in Brazil
investigating the efficacy of these interventions [16, 17],
and only one randomized controlled study has been pub-
lished to date [18].
Considering this context, University of Sa˜o Paulo
researchers established a partnership with the Sa˜o Paulo
AIDS Program to conduct a broader project to develop,
implement and analyze a psychosocial intervention and its
acceptability, feasibility and effectiveness within the Bra-
zilian Unified Health System (SUS).
The intervention drew on the references which have
distinguished the ethical and theoretical framework
underlying the Brazilian Response to AIDS (BRA) [19,
20], more specifically, its human rights-based approach
[21–23]. Non-discrimination and participation are core
components of the right to health, and of human rights-
based responses to AIDS, as well as the principles of
availability, accessibility, acceptability and quality of the
services delivered, ensuring the most vulnerable popula-
tions are reached with the services they need [24]. In a
debate published in the Lancet, Kalichman and Diniz [25]
noted that mortality and incidence decreased following this
rights-based approach providing the necessary evidence.
BRA would have never succeeded without the SUS prin-
ciple of universalidade (universal access), grounded in
constitutional rights for both prevention and treatment.1 A
common misunderstanding centers on the Unified Health
System (SUS) principle of integralidade (comprehensive-
ness) aimed to overcome the dichotomy between preven-
tion and treatment.
For two decades, integralidade and universalidade have
been key assets to the quality of services delivered and for the
high rates of adherence to ARV in Brazil, as previous studies
have shown [26]. Early in the 1990s, the National Aids
Program defended before the World Bank that treatment is in
itself a form of secondary prevention of complications,
reduces HIV transmission and bring affected people to the
health system for testing, counseling and early treatment [19,
25]. On the other hand, much of what was learnt in BRA
prevention policies focused on universal access and adher-
ence to condom use inspired the integralidade initiatives
enhancement of AIDS care and treatment [27].
Two characteristics of the intervention discussed in this
article are consistent with features of effective interven-
tions analyzed in international systematic reviews, namely,
the fact that it is an individual approach (compared to a
group approach) [28] and is aimed at non-adherent patients
[29]. It is also congruent with approaches that propose a
more radical replacement of the notions of adherence with
ideas that reflect ‘‘collaboration’’ [30], ‘‘autonomy moti-
vation’’ [31], ‘‘empowerment’’ [32] and the notion of
‘‘concordance’’ [33], as we have discussed elsewhere [30].
This paper discusses the results of a clinical trial that
evaluated the effectiveness of a psychosocial intervention
developed from previous BRA initiatives that conceptual-
ize health care as inextricably linked to prevention [34–36],
especially based on the concept of Care (Cuidado) [30, 37]
and its psychosocial constructionist approaches [38–40].
Objective
The aim of this study was to evaluate the effectiveness of a
social-psychological individual intervention for improving
adherence to antiretroviral drug regimens for HIV.
Methods
Study Setting
This study was conducted in 2008, from March to November,
at the STI/AIDS Training and Reference Center of Sao Paulo
State, Brazil (CRT-DST/AIDS), a traditional ‘‘gold stan-
dard’’ reference center for integralidade and interdisciplin-
ary approaches for the Brazilian Aids Response (BRA),
which has provided more than two decades of care. At that
present time assisted over 4,000 PLHIV, attracting patients
coming from different parts of the metropolitan area, from
other cities and regions of the country. The CRT-DST/AIDS
1 For a deeper understanding of Brazilian Unified Health System see
the Lancet The Brazil Series that critically examines what the
country’s policies have achieved and where future challenges might
lie, accessible at http://www.thelancet.com/series.
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has been an operational research center for SUS. It has per-
manent multi-disciplinary forums comprising nurses, psy-
chologists, social workers and dental surgeons, infectious
disease physicians and other specialists (psychiatrist, neu-
rologist, cardiologist, endocrinologist, urologist, proctolo-
gist, dermatologist, etc.).
Participants
Clients of the service older than 18 years of age with a
blood-detectable HIV viral load of more than 50 copies/ml
and undergoing treatment with the same antiretroviral
regimen for at least six months prior to the date of viral
load results from exams done at recruitment, were invited
to take part in this study (preliminary criteria). A detectable
Viral Load after 6 months in use of HAART in the absence
of proven viral resistance, strongly suggests an adherence
problem [41]. The following exclusion criteria were
applied: a) pregnancy (adherence issues are diverse and
specific); b) having a physically or mentally disabling
disease which prevents individual from visiting the service
or taking part in the proposed activities; c) in treatment for
hepatitis B or C, or for active opportunistic disease (to
prevent accumulation of other types of medication); d)
previous inclusion in any other clinical trials, a requirement
for any research at the Center.
Sample Size
The sample size was calculated to detect a difference in the
average adherence (primary study measure) of 20 %
between the Intervention and Control Groups at the end of
study, considering 30 % of estimated average adherence in
the Control Group, with a confidence interval of 95 %,
power (1-b = 0.80 and a error = 0.05). Sample size was
estimated at 100 subjects per group, allowing for 10 %
refusal. A post hoc power analysis was performed to
evaluate the primary study measures of adherence and also
to at 1 and 6 months.
Recruitment and Allocation
A list of adult patients who met the preliminary eligibility
criteria were contacted briefly at their appointment by a
member of the research team who invited them to an
interview. Those who did not have an appointment during
the recruitment period were contacted by phone. In the pre-
scheduled interview, a nurse from the research team
assessed the exclusion criteria and potential subjects were
informed about the aims of the study, its duration, inter-
vention and procedures. Those who agreed to participate
proceeded to the informed consent process. Participants
were, then, randomized at a 1:1 ratio and allocated into
either the Intervention Group (IG) or the Control Group
(CG).
A computer-randomized number list was produced by
an independent statistician and kept under lock and key at
the Research Unit (RU) of the CRT/DST/AIDS in accor-
dance with its ethical procedures. The allocation was car-
ried out after the baseline interview when the nurse
contacted the person in charge of the computer-randomized
list at the RU by phone, informing the patient ID number.
The nurse was then furnished with the allocation (IG or
CG) according to the list sequence. The study procedures
were approved by the CRT-DST/AIDS review board, as
required by the National Ethics Committee of the Brazilian
Ministry of Health.
Intervention Description
The structure of the intervention (Table 1) consisted of
four individual 1 hour meetings held every fifteen days by
previously trained health professionals according to the
following guidelines.
Goal
The intervention was conceived as Cuidado (Care), a
process aimed at ‘‘technical success’’ (good clinical out-
come). Technical success depends ‘‘on practical success,
i.e., the ability of health care to focus, beyond the clinical
outcome, on the health-related aspirations of patients, and
should include a negotiation of the best possible outcome
given the patient’s life plan and well-being at the time’’
[30]. Practical success constitutes greater convenience for
the patients based on their own definition of a ‘‘good life’’
and is a good marker of the human rights principle of non-
discrimination and acceptability.
Method
Decoding and overcoming limiting situations shall be
defined as the core of a shared process of collaboration
towards Cuidado, based on professional-patient mutual
recognition, conversation and dialogue. The patient is
conceived as the expert on their daily life whereas the
professional is conceived as the expert on the technical side
of medical practice and health promotion [40].
Dialogue, a good marker if participation that enhance
quality of care, should focus on daily routine ‘‘scenes’’ that
expressed (coding) real experiences of ARV and medica-
tion intake. Conversation should reach the deepest under-
standing of each inter-subjective context dynamic of the
intake scene, amplified to the comprehension of social,
cultural and structural scenery [38–40]. The dialogue
focused on the ‘‘person in scene’’ mirrors the ‘‘coding–
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decoding’’ process as proposed by Paulo Freire [42] ped-
agogic constructionist approach; it is also based on social
constructionist dramaturgical approaches to human inter-
action applied to the AIDS responses, which consider
gender and sexuality inequalities as well as processes of
stigmatization and discrimination [40, 43–48].
Ethical Horizon
Patient individuality and autonomy must be respected, with
patients recognized as having rights and being entitled to the
constitutional right to non-discrimination and to universal,
integral (comprehensive) care, treatment and prevention.
Table 1 Summary of objectives and structure of ACCA* intervention
Session 1 Session 2 e 3 Session 4
Objectives Contract; Increase knowledge about
treatment;
Deeper understanding of feasible and desired
changes in context and personal conduct
aiming at self-care and enhancement of
patient-clinic quality of communication and
care;
Identify situations ant context of daily life
that are obstacles for treatment;
Understand and decodify real life
scenes;
Identify resources to pursue and sustain
chosen paths to face difficulties with ARV
treatment;
Organize priority issues and decide on
themes to be part of next conversations;
Amplify daily scene to bigger
programmatic and social context;
Close the process.
Clarify most technical question about
treatment.
Foster creative and active
imagination about daily life
Foster new personal repertoires to
face identified obstacles to
treatment.
Themes Mutual recognition of patient as experts
on daily life and professionals-
researchers as technical experts;
Questions about treatment; Questions about treatment;
The overview of patients’ social and
inter-subjective context;
Real episodes where treatment is
not followed;
Reviewing paths, solutions and repertoires;
Question about treatment. Paths to face obstacle and ‘‘in
scene’’ solutions.
Talking about how to face future obstacle and
difficulties and sustain changes;
Final clarification and orientation on the
research process.
Methodology Talking about the procedure, aim and
contract;
Reviewing contract and questions; Reviewing contract and questions;
Free conversation and careful listening
about the person’s life
Looking at typical episodes of
non-adherence
Taking and exploring scene from real
episodes;
Focus questions about treatment and on
situations and episodes where following
treatment is difficult;
The participant chosen their
priority from list of problems;
Decoding the scenes, and through active
imagination and role-playing reinvent
them;
Use of informative resources(folders,
guidelines, adherence kits);
Taking and exploring scenes from
real episodes;
Inform on social and programmatic
resources, as well as constitutional rights
Records specific situations and episodes
that seem to be more important to cope
on recording sheets
Decoding the scenes, and through
active imagination and role-
playing reinvent them;
Constitutional rights;
Recording decisions and plans for the future
on recording sheets.
Talking about obstacle that are
beyond individual action, and
shared by other PLHIV;
Discussing individual and
programmatic resources;
Professional and participant record
and organizing a hierarchy of
scenes and situations on
recording sheet
* ACCA is the acronym for ‘‘Abordagem Construcionista do Cuidado em Adesa˜’’(Constructionist Care Approach to Adherence)
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Close supervision of researchers—nurses, psychologists
and social workers with previous experience in AIDS
Reference Centers—was carried out based on recording
sheets and the personal reports produced by them. All
meetings were tape-recorded.
In this constructionist approach, the professional acts as
a ‘‘director’’ of an ‘‘imaginary drama’’. Conversations look
for real episode narratives focusing on scripts and charac-
ters in action, the ARV intake scene dynamics in this case.
Lists of problems, behaviors, attitudes, believes, knowl-
edge, motivations and emotions are approached through
real life scenes, chosen by the professional. Scenes are
conceived as embodied scripts, situated in the broader
social context where gender, social status and power
imbalances are constructed. Without leaving the typical
two-chairs-one-table ambulatory setting, spontaneity is
increased as the professional explores positions and role
changes by requesting the patient to be, for a moment, in
the other person’s shoes or to change their own scripts,
supporting them to actively re-invent the scene. The deeper
and shared understanding of the daily medication intake
obstacle dynamic occurs when the ‘‘medication taker’’ can
be seen in their role, as well as the roles of ‘‘others’’, and
can see their scenery in a clearer and fuller manner, by
exploring scene meanings in the capacity of spectator from
an outside perspective, while using active imagination to
test new performances and scenes. Patient and professional
conclude by exploring viable new plans of action. Beyond
sharing the deeper understanding of daily life, professional
technical knowledge and practical experience of the person
in scene, which includes learning from situations experi-
enced by other patients, are shared as testimonies of pro-
fessional expertise.
Usual Care
Participants from the control group received only usual
care. Both intervention and control group participants
attended routine consultations with their assisting physi-
cian scheduled every 2 months, or more frequently when
clinically indicated. The medical consultations lasted
40 min on average. A reference team that comprised a
physician, psychologist and social worker saw all partici-
pants. Adherence was approached in a range of different
initiatives. Specifically, the physicians and nurses investi-
gated the use of medication in accordance with the pre-
scription, difficulties related to medication use and adverse
effects, and sought to adjust the timing of medications to
suit the daily routine of the patients. Medical specialists
saw participants when necessary.
All participants had an appointment with nurses who
read the MEMS caps (Medication Event Monitoring
System, AARDEX, Ltd., Zug, Switzerland) and assessed
how they were coping with this tool. The nurses also
encouraged adherence to the study, representing important
input to the intervention process.
Outcome Measures
Adherence Measures
MEMS caps were used as an electronic monitoring device.
Subjects received their medicines from the pharmacy in
bottles with MEMS caps, and after two months of follow-
up were randomized to receive intervention or standard
care. Two medicines were monitored independently of the
antiretroviral regimen. If antiretroviral regimen was more
complex (more than two drugs), the drug with the highest
number of pills or frequency of doses or adverse effects,
was chosen.
Participants returned to collect their medicines monthly
and their adherence was measured using the electronic
monitoring device at weeks 8 (pre intervention), 12, 16
(intervention period), 20 and 24 (post intervention period).
The adherence measure was estimated based on per-
centage of doses taken (total dose taken divided by total
doses prescribed multiplied by 100), percentage of doses
taken on time (accepted variation tolerance of up to 25 %
above or below) and according to the proportion of indi-
viduals who took 95 % or more of doses prescribed.
Viral Load
HIV1 RNA levels were assessed by VERSANT-HIV-1
RNA 3.0 b-DNA Essay, detection limits = 50 copies/ml—
Bayer Health Care—b-DNA Analyzer System 340 in the
CRT/DST/AIDS laboratory. Viral load expressed in logs
was measured both at baseline and at the end of the study.
Statistical Analysis
The analysis was done through intention-to-treat. Groups
were first compared for covariables obtained at baseline in
order to verify any differences at time of inclusion that
could have potentially interfered with outcomes. Results
were analyzed by comparing means (Student’s t test) and
proportions (Pearson’s Chi-square test) of outcome vari-
ables between CG and IGs. During follow up, variations in
mean outcomes at study baseline were compared against
subsequent measurements using Student’s paired t test for
means, and McNemar’s test for proportions. Kruskal–
Wallis and Wilcoxon’s non-parametric tests were applied
when the distribution type of the study variables did not
have a normal distribution. Linear regression was also
calculated for proportion of individuals with adherence of
greater than or equal to 95 % by groups (normality and
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homoscedasticity was examined) at baseline, and at 30, 60
and 90 days’ follow-up, using the coefficient of straight-
line angle and coefficient of determination (r2). The level
of statistical significance was set at a value of p \ 0.05.
Results
Of a total of 566 patients who had viral load exams per-
formed within four months of study commencement, 363
eligible subjects were identified and underwent the
recruitment process between 13th March and 28th May,
2008. Of the eligible group, 121 agreed and 240 refused to
take part in the study while two individuals were excluded
(1 pregnancy and 1 presenting with active opportunistic
disease). Among refusal reasons, the need to attend the
service more frequently than routine care was indicated by
18 % of participants. Fifteen percent did not show up after
first contact and other 8 % argued that they lived in another
city. The remaining refusal motives were scattered.
The enrollment, group allocation, follow-up and data
analysis are depicted in the diagram constructed according
to CONSORT guidelines (Fig. 1). No statistically signifi-
cant difference between the IG and the CG was found for
Fig. 1 Flow diagram of
patients’ progress throughout
the study
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the variables collected in the beginning of the study, as
shown in Table 2.
Mean time in the study was similar for both groups (IG
159.1 days SD = 67.0 vs. CG 165.1 days SD = 61.361,
t test = 0.514; p = 0.61). Frequency of visits to the service
for other activities was also similar for both groups (IG 8.8
SD = 5.4 vs. CG 8.3 SD = 5.2, t test = 0.517; p = 0.61).
The mean interval between study intervention visits was
21 days.
The overall retention rate was 83.4 % (79.6 % in the IG,
and 89.4 % in the CG) at the end of the intervention. Forty-
four participants attended all four meetings, corresponding
to 69 % of the participants randomized into the IG.
Retention was 80.9 % (78.1 % in IG, and 84.2 % in CG) at
the first follow up after the end of intervention, and 78.5 %
(75 % in IG and 82.4 % in the CG) at the end of the study.
During the first two months of use of the electronic
monitoring device, the percentage of adherence for doses
taken ranged from 85.9 (1st month) to 78.0 % (2nd month)
in the IG, and from 82.3 (1st month) to 77.5 % (2nd month)
in the CG, with no significant differences. The proportion
of adherent participants (95 % adherence or greater) ran-
ged from 50.9 (1st month) to 36.8 % (2nd month) in the IG,
and from 49 (1st month) to 50.9 % (2nd month) in the CG.
The adherence values for the second month were taken as
the baseline measures prior the Intervention.
No statistically significant differences were found
between the adherence percentages for doses taken in the
IG and the CG for the five measurements obtained, as
shown in Table 3. Considering this measure, the power at
the end of the study was 3.5 %. However, the fall in
adherence in the IG observed at the second follow up
(120 days) was statistically significant (Wilcoxon test
z = 2.251; p = 0.02). No falls in adherence percentages
were found for the CG at the follow up periods.
No statistically significant difference was found between
the adherence percentages for taking medication according
to the prescribed time regimen in the IG and the CG, for the
five measurements obtained, as shown in Table 4. Con-
sidering this measure, the power of the study was 12.0 %.
Table 2 Socio-demographic and epidemiological characteristic of







Male 40 (62.5) 36 (63.2) 0.94a
Age (years)
Mean ± SD 42.8 ± 7.7 42.9 ± 8.6 0.97b
Schooling, n (%)
Primary 29 (45.3) 20 (35.1) 0,47a
Secondary 22 (34.4) 22 (34.4)
Higher 13 (20.3) 12 (21.1)
Time with HIV (months)
Mean ± SD 134.7 ± 63.8 144.1 ± 57.7 0.39b
Time under ART (months)
Mean ± SD 99.8 ± 50.0 105.4 ± 44.2 0.52b
Adverse Effects, n (%)
Yes 28 (43.8) 29 (50.9) 0.43a
Viral load (Log)
Mean ± SD 3.4601 ± 1.1967 3.3046 ± 1.0944 0.47b
Smoking, n (%) 32 (50.0) 21 (36.8) 0.15a




Less than once a
month
47 (74.6) 38 (66.7)
Less than once a
week
4 (6.4) 2 (3.5)
Weekly or more 12 (19.0) 17 (29.8 %)
Cannabisc 0.08a
Less than once a
month
57 (91.9) 44 (78.6)
Less than once a
week
0 (0.0) 2 (3.5)
Weekly or more 5 (8.1) 10 (17.9)
Cocainec
Less than once a
month
62 (98.4) 50 (87.7) 0.06a
Less than once a
week
0 (0.0) 1 (1.8)
Weekly or more 1 (1.6) 6 (10.5)
Common mental
disorders, n (%)
48 (75.0) 45 (79.0) 0.61a
a Chi-square test
b t student test
c missing or excluded
Table 3 Adherence percentages for doses taken, measured by





































* Kruskal–wallis test with 1 d.f.; all p [ 0.05
AIDS Behav (2013) 17:181–192 187
123
The fall in adherence in the IG at the first and second
follow ups (90 and 120 days) was statistically significant
(Wilcoxon test z = 2.535; p = 0.01 and z = 2.805;
p = 0.005, respectively). In the CG, no falls in adherence
percentages were found at the follow up periods.
No statistically significant difference was found between
the proportion of patients with adherence greater than or
equal to 95 % of doses taken in the IG and the CG, for the
five measurements obtained, as shown in Table 5. Con-
sidering this measure, the power at the end of the study was
9.9 %. In the IG, a fall in the proportion of adherents was
seen at the second follow up (120 days) but did not reach
statistical significance (Exact test value of p = 0.09). No
falls in adherence percentages were found for CG at the
follow-up periods.
Figure 2 shows the linear regression for the proportion
of individuals with adherence greater than or equal to 95 %
(95 % Confidence Interval) at the commencement of the
intervention and at 30, 60 and 90 days of follow up, by
group (Intervention and Control).
With regard to the secondary outcome measurement,
only 80 volunteers had viral load exams available at the
end of study. Among these 80 participants, there was no
significant difference between the IG and the CG in terms
of the proportion of patients with detectable viral load at
the beginning of the study that evolved to undetectable
viral load at the end of the study.
We also recalculated the initial viral load for these
patients, yielding a result of 3.2573 Log in the IG and
3.2689 Log in the CG. No statistically significant differ-
ence in final viral load values was found between the
Intervention (n = 44) and Control (n = 36) Groups,
2.4390 ± 1.4611 Log versus 2.3086 ± 1.3567 Log,
respectively, (t test = 0,4100; p = 0.68). Nevertheless, a
slight decrease in viral load was observed between study
baseline and endpoint in both groups, Intervention 3.2573
Log versus 2.4390 Log (Paired t test = 3.484; p \ 0.01)
and Control 3.2689 Log versus 2.3086 Log (Paired
t test = 4.332; p \ 0.0001).
The fall in viral load was greater in study participants
compared to those who refused to take part in the study.
The viral load at the end of study was 2.3803 Log in
Table 4 Adherence percentages for doses taken at prescribed time,








































* Kruskal–wallis test with 1 d.f.; all p [ 0.05
Table 5 Proportion of patient with adherence percentages greater







































* Chi Square test 1 d.f.: all p [ 0.05
Fig. 2 Linear regression of proportion of patient’s adherence greater
than 95 % by group (Intervention and control)
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volunteers and 2.8536 Log in refusers, with a value of
p \ 0.05.
Discussion
Baseline measures of adherence rate—86 % in the IG and
81.6 % in the CG—were higher than expected. Furthermore,
electronic monitoring typically achieves lower adherence
than pill counting while pill counting attains lower adherence
than self-reports [49, 50]. The Hawthorne effect [51], will-
ingness to participate, and MEMS caps use for two months
prior to the intervention may have previously increased mean
adherence. The fall in adherence between the first and second
month, when supposedly MEMS caps was an easier routine
for participants, may be evidence of this effect.
The increased care given to the patients during the study
period, which led to more visits to the service as well as
differentiated attention provided to both Control and
Intervention groups, may have contributed to increased
adherence to the anti-retroviral therapy by all participants
involved in this study. Other uncontrolled factors present in
this study may have promoted a strong response in the CG,
thereby minimizing any differences [52].
The adherence percentages according to doses taken and
to time regimen prescribed, as well as the proportion of
patients with adherence of greater than or equal to 95 %,
did not differ significantly between the IG and CG.
The proportion of patients with adherence greater than or
equal to 95 % during the intervention period and the first
follow-up period however, showed a tendency toward
increased adherence in the IG, and reduced adherence in the
CG, although this did not reach statistical significance
(Fig. 2). The decrease in adherence observed after the end of
the intervention solely in the IG presented statistical signif-
icance, and supports the hypothesis that this may have
stemmed from the effects of the intervention, given that both
groups were equally exposed to the effect of MEMS. Other
studies have shown that adherence levels do not persist after
the intervention, tending to decline over time [53, 54].
The increases in adherence promoted by complex
interventions, even the most effective of these interven-
tions, has proved to be limited [55]. Simoni et al. [56]., in a
recent meta-analysis of randomized controlled trials which
assessed the impact of stimulus interventions on adherence
to antiretroviral therapy, noted a 1.5-fold likelihood of
intervention participants attaining 95 % adherence. To
date, there is no evidence that low adherence can be rem-
edied in a definitive manner. Therefore, strategies to
enhance adherence should be continued throughout the
treatment period [55] and include periodical actions aimed
at enhancing adherence, particularly among individuals
who struggle to manage their treatment [29, 53].
The sole previous randomized controlled study of an
intervention to enhance adherence to ARV conducted in
Brazil [18] was held in the State of Bahia and used self-
reports to measure adherence. Results also showed no
effect of the intervention on adherence. Van Dulmen et al.
[57]. analyzed 38 systematic reviews focused on chronic
disease adherence interventions and revealed that half of
these had no effect on adherence.
Measurements of secondary outcomes also showed no
effect when comparing viral load between IG and CG.
However, the fall detected in both groups of 0.82 log in the
IG and 0.96 log in the CG, between study baseline and end-
point, reached statistical and possibility clinical signifi-
cance, since falls of greater than 0.5 log correlate with
lower risk of disease progression [58].
The decline in viral load observed may have stemmed
from small increases in adherence among patients, in
conjunction with the potency of the therapeutic regimen
[3]. Comparison of the evolution of viral load between the
study participants and eligible individuals who refused to
take part, showed decreases in both groups, albeit to a
greater, statistically significant degree among participants
of the clinical trial. This finding suggests that participation
in the study in itself may have promoted an adherence-
enhancing effect which in turn led to the differences in
viral load detected between the two groups (participants of
the study vs. refusals).
This study was the second randomized, controlled trial
to increase ART adherence conducted in Brazil. As rec-
ommended by systematic reviews, adherence evaluation
was objective, assessed in different points of the inter-
vention and measured two months after its closure. Data
was analyzed by intention to treatment and clinical results
were also evaluated, an ethical requirement for these
studies that aim at other benefits, as viral replication con-
trol [59, 60].
We sought to overcome some of the drawbacks of pre-
vious studies noted by other authors by running this study
in a setting other than that of clinical efficacy trials [55,
56].
Lastly, it is important to emphasize that one of the
contributions of this study was demonstrating the viability
of running trials in health services by exploiting the
potential of human resources and materials available,
without introducing radical changes in the routines of
professionals and patients [61].
Limitations
The methodology originality and the short intervention
period required by the funders demanded stricter control of
its complexity. The venue option was the chosen reference
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and training center for an AIDS service that, compared to
most Brazilian services, is better qualified and used as a
benchmark. Given these constraints and limitations the
present study did not benefit from the running of previous
pilot studies, but may contribute to the design of future
interventions in services which treat PLHIV in the State of
Sa˜o Paulo.
The experience of the health care team, the CRT-DST/
AIDS facilities and its abundant and broad resources sup-
ported the study feasibility. In addition, the usual care
provided by this service of technical excellence, offering a
broad array of activities to encourage greater adherence,
may have been an additional factor reducing the difference
between the groups. Moreover, the Center’s differentiated
structure and history may demand further adaptation of the
intervention to other service contexts.
This study has several other potential limitations
resulting from this context. First, it was not possible to
recruit the number of volunteers initially envisaged for the
two groups. The number of eligible subjects in the service
was lower than expected and the quantity of refusals
resulted in a smaller than recommended sample.
Another limitation was patient attrition of 20 % in the
IG and 11 % in the CG. The higher attrition in the IG may
be related to the same reasons for refusal reported by those
who did not agree to participate, such as having to come
more frequently than usual to the health service. The
periodicity of every-15 days was not feasible for all
patients as assumed, and should be considered as a relevant
result in the adaptation in each service contexts. In the
routine care, periodicity may be tailored to each person
daily activities, to his/her working and domestic scenarios,
to the long distances they have to cover to assess the ser-
vices. Another paper will focus on process evaluation, in
order to discuss how to respond to the social and daily life
context of these patients who refused or abandoned the trial
because of other important daily life activities. Expected
differences (20 %) in adherence between the IG and CG
was overestimated in the sample size calculation. The
statistical power calculated post hoc did not exceed 12 %,
and was therefore lower than the 80 % power used for
sample size calculation.
Conclusions
The intervention did not increase adherence among study
participants. However, the reduced levels of viral load
detected in both groups may have benefited the study
participants because lower levels are associated with
reduced mortality and disease progression.
Interventions aimed at increasing treatment adherence
occur in the complex real daily life of health services, and
this factor must be considered when using this framework
or taking this structured intervention as an inspiration to
other initiatives. The assistance provided through the
intervention did not prove sufficient to impact adherence
levels at this service. Indeed, we continue to believe that
this population requires individualized attention that fosters
each person’s participation as part of the solution, not as
part of the problem, in line with the non-discrimination and
participation principles of human rights-based initiatives.
Investing in the development of in-depth, individualized
approaches aimed at promoting equity among individuals
more vulnerable to non-adherence and AIDS morbidity, as
well as at monitoring the Cuidado (Care) of patients with
known adherence problems toward more effective solu-
tions to tackle treatment problems, remains an ongoing
challenge for health services.
Ongoing qualitative analysis of the intervention will
yield further insights regarding the results of this pragmatic
clinical trial. After refining the intervention, similar studies
involving other less complex specialized services can be
conducted in a range of different care settings which more
closely reflect the prevailing reality of the national Unified
Health System (SUS) and its Brazilian AIDS Response
(BRA).
Acknowledgments Fundac¸a˜o de Amparo a Pesquisa do Estado de
Sa˜o Paulo (FAPESP) funded this study. We would like to acknowl-
edge the patients that participated in the research and, the health
providers of the STI/AIDS Training and Reference Center’, especially
Ana´lia Amorim, Analice de Oliveira and Karina Wolffenbu¨ttel
who conducted the intervention.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy
M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral
load, and development of drug resistance in an indigent popula-
tion. AIDS. 2000;14(4):357–66.
2. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier
C, et al. Adherence to protease inhibitor therapy and outcomes in
patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
3. Bangsberg DR. Less than 95 % adherence to nonnucleoside
reverse-transcriptase inhibitor therapy can lead to viral suppres-
sion. Clin Infect Dis. 2006;43(7):939–41.
4. FeA Acurcio, Puig-Junoy J, Bonolo PeF, Braga Ceccato MG,
Guimara˜es MD. Cost-effectiveness of initial adherence to anti-
retroviral therapy among HIV infected patients in Belo Hori-
zonte, Brazil. Rev Esp Salud Publica. 2006;80(1):41–54.
5. Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR,
Kimmel AD, et al. Projecting the cost-effectiveness of adherence
interventions in persons with human immunodeficiency virus
infection. Am J Med. 2003;115(8):632–41.
190 AIDS Behav (2013) 17:181–192
123
6. Munakata J, Benner JS, Becker S, Dezii CM, Hazard EH, Tierce
JC. Clinical and economic outcomes of nonadherence to highly
active antiretroviral therapy in patients with human immunode-
ficiency virus. Med Care. 2006;44(10):893–9.
7. Lamiraud K, Moatti JP. Economic implications of nonadherence
to highly active antiretroviral treatment in HIV patients. Expert
Opin Pharmacother. 2006;7(2):135–43.
8. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT,
Varney J, et al. A meta-analysis of the association between
adherence to drug therapy and mortality. BMJ. 2006;333(7557):15.
9. Wahl LM, Nowak MA. Adherence and drug resistance: predic-
tions for therapy outcome. Proc Biol Sci. 2000;267(1445):
835–43.
10. Nemes MIB, Beaudoin J, Conway S, Kivumbi GW, Skjelmerud
A, Vogel U. Evaluation of WHO’s contribution to ‘‘3 by 5’’: main
report. Geneva: World Health Organization, 2006.
11. Bennett S, Chanfreau C. Approaches to rationing antiretroviral
treatment: ethical and equity implications. Bull World Health
Organ. 2005;83(7):541–7.
12. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P,
et al. Adherence to HAART: a systematic review of developed
and developing nation patient-reported barriers and facilitators.
PLoS Med. 2006;3(11):e438.
13. WHO. Adherence to long-term therapies: evidence for action.
Geneva: World Health Organization; 2003.
14. Ministe´rio da Sau´de. Diretrizes para o fortalecimento das ac¸o˜es
de adesa˜o ao tratamento para pessoas que vivem com HIV e Aids.
In: Coordenac¸a˜o Nacional de DST/Aids, editor. Brası´lia. Brasil:
Ministe´rio da Sau´de 2008.
15. Caraciolo JMM, Santa Helena ET, Basso CR, Souza RA, Silva
MH, Ada˜o VM, et al. Intervention to enhance HAART adherence
in HIV/Aids health services in the State of Sa˜o Paulo, Brazil,
2007. Saude Soc. 2009;18 suppl 2:78–93.
16. Garcia R, Ponde´ M, Lima M, Souza AR, Stolze SM, Badaro´ R.
Lack of effect of motivation on the adherence of HIV-positive/
AIDS patients to antiretroviral treatment. Braz J Infect Dis. 2005;
9(6):494–9.
17. Gupta N, Silva AC, Passos LN. The role of integrated home-
based care in patient adherence to antiretroviral therapy. Rev Soc
Bras Med Trop. 2005;38(3):241–5.
18. Sampaio-Sa M, Page-Shafer K, Bangsberg DR, Evans J, Dourado
Mde L, Teixeira C, et al. 100 % adherence study: educational work-
shops versus video sessions to improve adherence among ART-naı¨ve
patients in Salvador, Brazil. AIDS Behav. 2008;12(Suppl 4):S54–62.
19. Berkman A, Garcia J, Munoz-Laboy M, Paiva V, Parker R. A
critical analysis of the Brazilian response to HIV/AIDS: lessons
for controlling and mitigating the epidemic in developing coun-
tries. Am J Public Health. 2005;95(7):1162–72.
20. Paim J, Travassos C, Almeida C, Bahia Ligia, Macinko J. The
Brazilian health system: history, advances and challenges. Lan-
cet. 2011;377(9779):1778–97.
21. Mann J, Tarantola D, editors. AIDS in the world II. New York:
Oxford University Press; 1996.
22. Ayres JRCM, Paiva V, Franc¸a JR I. From natural history of
disease to vulnerability: changing concepts and practices in
contemporary public health. In: Sommer RPaM, editor. Routl-
edge Handbook in Global Public Health. 1 edition ed. Abingdon,
Oxon: T & F Books; 2011. p. 98–107.
23. Ayres J. Access to AIDS treatment: appropriateness and cor-
rectness in the pursuit of good practice. Cad Saude Publica.
2006;22(4):705–31.
24. Gruskin S, Tarantola D. Universal Access to HIV prevention,
treatment and care: assessing the inclusion of human rights in
international and national strategic plans. AIDS. 2008;22(Suppl 2):
S123–32.
25. Kalichman A, Diniz S. AIDS treatment in Brazil: what kind of
evidence do we need? Lancet. 2009;374(969):1066.
26. Nemes MI, Carvalho HB, Souza MF. Antiretroviral therapy
adherence in Brazil. AIDS. 2004;18(Suppl 3):S15–20.
27. Paiva V, Teixeira P, Shimma E. What is being done to improve
ARV therapy in Sa˜o Paulo, Brazil. XIII International AIDS
Conference; Durban: Marathon Multimidia; 2000.
28. Rueda S, Park-Wyllie LY, Bayoumi AM, Tynan AM, Antoniou
TA, Rourke SB, et al. Patient support and education for pro-
moting adherence to highly active antiretroviral therapy for HIV/
AIDS. Cochrane Database Syst Rev. 2006;3:CD001442.
29. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral
therapy adherence interventions: a research synthesis of trials,
1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285–97.
30. Nemes M, Helena E, Caraciolo J, Basso C. Assessing patient
adherence to chronic diseases treatment: differentiating between
epidemiological and clinical approaches. Cad Saude Publica.
2009;25:S392–400.
31. Williams GC, Rodin GC, Ryan RM, Grolnick WS, Deci EL.
Autonomous regulation and long-term medication adherence in
adult outpatients. Health Psychol. 1998;17(3):269–76.
32. Feste C, Anderson RM. Empowerment: from philosophy to
practice. Patient Educ Couns. 1995;26(1–3):139–44.
33. Britain. RPSoG. From compliance to concordance: toward shared
goals in medicine taking. London: Royal Pharmaceutical Society
of Great Britain; 1997.
34. Ayres JRCM, Paiva V, Franc¸a I Jr, Silva NGd, Lacerda R, Negra
MD, et al. Vulnerability, human rights, and comprehensive health
care needs of young people living with HIV/AIDS. Am J Public
Health. 2006;96:1001–6.
35. Paiva V, Ayres J, Grusking S. Being young and living with HIV:
the double neglect of sexual citizenship. Routledge Handbook of
Sexuality, Health and Rights. New York: Taylor & Francis
Group; 2010. p. 422–430.
36. Paiva V, Ayres J, Franc¸a I Jr. Expanding the flexibility of nor-
mative patterns in youth sexuality and prevention and care pro-
grams. In: Sexuality Research & Social Policy. Journal of NCRC
Access at http://nsrc.sfsu.edu. 2004;1 Suppl 1.
37. Ayres JR. O cuidado, os modos de ser (do) humano e as pra´ticas
de sau´de. Saude Soc. 2004;13(3):16–29.
38. Benzaken A, Galban Garcia E, Sardinha J, Paiva V. Community-
based intervention to control STD/AIDS in the Amazon region,
Brazil. Rev Saude Publica. 2007;41:118–26.
39. Paiva V, Garcia J, Rios L, Santos A, Terto V, Muno˜z-Laboy.
Religious communities and HIV prevention: an intervention study
using a human rights-based approach. Health. GP, editor. 2010.
40. Paiva V. Analysing sexual experiences through ‘‘scenes’’: a
framework for the evaluation of sexuality education. Sex Educ.
2005;5(Suppl 4):345–58.
41. WHO. Antiretroviral therapy for HIV infection in adults and
adolescents: recommendation for a public health approach. In:
HTM/HIV, editor. Geneva, Switzerland: WHO Library Catalo-
guing-in-Publication Data; 2006 rev.
42. Freire P. Pedagogy of the oppressed. 30th ed. New York: The
continuum International Publishing Group Inc; 2006. p. 195.
43. Anggleton P, Parker R (Org). Routledge Handbook of Sexuality,
Health and Rights. 1 ed. New York: Taylor & Francis Group;
2010.
44. Parker R, Aggleton P. Introduction. Sexuality, Culture and
Health. Routledge Handbook of Sexuality, Health and Rights.
2nd edition. New York. 2007. p. 1-13.
45. Paiva V. Gendered scripts and the sexual scenes: promoting
sexual subjects among Brazilians teenagers. In: Aggleton RPP,
editor. Sexuality, Culture and Health. 2nd ed. New York: Taylor
& Francis Group; 2007. p. 427–43.
AIDS Behav (2013) 17:181–192 191
123
46. Maluwa M, P’ A. RG. P. HIV and AIDS-related stigma, dis-
crimination and human rights. A critical overview. Health and
Human Rights. 2002;6(1):1–18.
47. Parker RG, Aggleton P. HIV and AIDS-related stigma and dis-
crimination: a conceptual framework and implications for action.
Soc Sci Med. 2003;57(1):13–24.
48. Garrido PB, Paiva V, do Nascimento VL, Sousa JB, Santos NJ.
AIDS, stigma and unemployment: implications for health ser-
vices. Rev Saude Publica. 2007;41(Suppl 2):72–9.
49. Paterson DL, Potoski B, Capitano B. Measurement of adherence
to antiretroviral medications. J Acquir Immune Defic Syndr.
2002;31(Suppl 3):S103–6.
50. Vriesendorp R, Cohen A, Kristanto P, Vrijens B, Rakesh P,
Anand B, et al. Adherence to HAART therapy measured by
electronic monitoring in newly diagnosed HIV patients in Bots-
wana. Eur J Clin Pharmacol. 2007;63(12):1115–21.
51. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence
with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):
56–66.
52. Wohl AR, Garland WH, Valencia R, Squires K, Witt MD,
Kovacs A, et al. A randomized trial of directly administered
antiretroviral therapy and adherence case management interven-
tion. Clin Infect Dis. 2006;42(11):1619–27.
53. Wagner GJ, Kanouse DE, Golinelli D, Miller LG, Daar ES, Witt
MD, et al. Cognitive-behavioral intervention to enhance adher-
ence to antiretroviral therapy: a randomized controlled trial
(CCTG 578). AIDS. 2006;20(9):1295–302.
54. Johnson MO, Charlebois E, Morin SF, Remien RH, Chesney MA,
Team NIoMHHLP. Effects of a behavioral intervention on
antiretroviral medication adherence among people living with
HIV: the healthy living project randomized controlled study.
J Acquir Immune Defic Syndr. 2007;46(5):574–80.
55. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Inter-
ventions for enhancing medication adherence. Cochrane Data-
base Syst Rev. 2008;16 Suppl 2:CD000011.
56. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N.
Efficacy of interventions in improving highly active antiretroviral
therapy adherence and HIV-1 RNA viral load. A meta-analytic
review of randomized controlled trials. J Acquir Immune Defic
Syndr. 2006;43(Suppl 1):S23–35.
57. van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R,
Bensing J. Patient adherence to medical treatment: a review of
reviews. BMC Health Serv Res. 2007;7:55.
58. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA,
Struble KA. The use of plasma HIV RNA as a study endpoint in
efficacy trials of antiretroviral drugs. AIDS. 1999;13(7):797–804.
59. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R.
Patient adherence to HIV medication regimens: a review of
published and abstract reports. Patient Educ Couns. 2002;46(2):
93–108.
60. McDonald HP, Garg AX, Haynes RB. Interventions to enhance
patient adherence to medication prescriptions: scientific review.
JAMA. 2002;288(22):2868–79.
61. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials:
increasing the value of clinical research for decision making in
clinical and health policy. JAMA. 2003;290(12):1624–32.
192 AIDS Behav (2013) 17:181–192
123
